Health Economics›Esophageal cancer›Metastatic or locally advanced disease subsequent lines of therapy

Metastatic or locally advanced disease subsequent lines of therapy

Esophageal cancer · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 5 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Erlotinib monotherapy Variant #01	—	R 13 907	28d	~9.7 mo	~8.8 mo	~11	~R 152 976 PFS proxy · indirect	30
Docetaxel and Irinotecan Variant #01	—	R 2 573	21d	—	—	—	—	—
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	—	~9.2 mo	—	—	1
IRI-S Variant #01 Partial	—	R 1 603	28d	3.8 mo	—	5	R 8 016 PFS proxy	1
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	~1.8 mo	~6.3 mo	~2	~R 486 PFS proxy · indirect	10
Irinotecan monotherapy N/A - secondary systemic drug	—	R 47	42d	~2.3 mo	~8.5 mo	~2	~R 95 PFS proxy · indirect	16
CAPIRI N/A - secondary systemic drug	—	R 1	21d	~5.9 mo	~16.8 mo	~9	~R 12 PFS proxy · indirect	2
Placebo Partial	—	—	—	~3.0 mo	~6.7 mo	—	—	38
S-1 monotherapy Variant #01 Partial	—	—	21d	1.7 mo	—	3	—	1

9 of 9 regimens shown